- references:
  - doi: 10.1126/science.abd0827
    firstAuthor:
      surname: Hansen
      givenNames: Johanna
    year: 2020
    journal: Science
  - doi: 10.1126/science.abd0831
    firstAuthor:
      surname: Baum
      givenNames: Alina
    year: 2020
    journal: Science
  - doi: 10.1101/2020.08.02.233320
    firstAuthor:
      surname: Baum
      givenNames: Alina
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: REGN10933 +REGN10987
  company: Regeneron
  phase: III
  clinicalTrials: |-
    NCT04425629 (Outpatient; Phase I, II, III; n=2100)
    NCT04426695 (Hospitalized; Phase I, II, III; n=2970)
    NCT04452318 (Prevention; Phase III)
    NCT04519437
- references: []
  antibodies:
  - name: LY3819253
  company: Lilly / AbCellera
  phase: III
  clinicalTrials: |-
    NCT04411628 (Phase I; n=40)
    NCT04497987 (Prevention; Phase III; n=2400)
    NCT04518410 (Outpatients; Phase III; n=2000)
    NCT04501978
- references: []
  antibodies:
  - name: TY027
  company: Tychan Pte
  phase: I
  clinicalTrials: |-
    NCT04429529
- references:
  - doi: 10.1038/s41586-020-2381-y
    firstAuthor:
      surname: Shi
      givenNames: Rui
    year: 2020
    journal: Nature
  antibodies:
  - name: JS016
  company: Shanghai Junshi Bioscience
  phase: I
  clinicalTrials: |-
    NCT04441918
- references: []
  antibodies:
  - name: BRII-196
  company: Brii Biosciences
  phase: I
  clinicalTrials: |-
    NCT04479631
    NCT04479644
- references: []
  antibodies:
  - name: AZD7442 (AZD8895 and AZD1061)
  company: AstraZeneca / Paraxel
  phase: I
  clinicalTrials: |-
    NCT04507256
- references: []
  antibodies:
  - name: CT-P59
  company: Celltrion
  phase: I
  clinicalTrials: |-
    NCT04525079
- references: []
  antibodies:
  - name: MW33
  company: Mabwell Bioscience
  phase: I
  clinicalTrials: |-
    NCT04533048
- references: []
  antibodies:
  - name: BGB DXP593
  company: BeiGene
  phase: I
  clinicalTrials: |-
    NCT04532294
- references: []
  antibodies:
  - name: STI-1499
  company: Sorrento Therapeutics
  phase: I
  clinicalTrials: |-
    NCT04454398
- references: []
  antibodies:
  - name: SCTA01
  company: Sinocelltech
  phase: I
  clinicalTrials: |-
    NCT04483375
- references:
  - doi: 10.1038/s41586-020-2349-y
    firstAuthor:
      surname: Pinto
      givenNames: Dora
    year: 2020
    journal: Nature
  antibodies:
  - name: VIR-7831
  company: Vir Biotechnology, GSK
  phase: III
  clinicalTrials: |-
    NCT04545060
